CEO Brian Lian highlighted the company's progress in advancing its VK2735 obesity program, with Phase 3 trials for the subcutaneous formulation set to begin later in Q2 2025. Additionally, enrollment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback